MorphoSys kündigt Präsentationen klinischer Daten auf der Jahrestagung der American Society of Hematology (ASH) 2016 an
03 nov. 2016 09h45 HE
|
Morphosys AG
Martinsried / Munich, Germany, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Vorträge zu firmeneigenen Antikörperprogrammen MOR208 und MOR202 Die MorphoSys AG (Frankfurt: MOR; Prime Standard Segment,...
MorphoSys and LEO Pharma Enter into Strategic Alliance to Develop Therapeutic Antibodies in Dermatology
02 nov. 2016 02h34 HE
|
MorphoSys AG
MARTINSRIED / MUNICH, Germany, Nov. 2, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) and LEO Pharma today announced that they have entered into a...
MorphoSys to Host Q3 2016 Conference Call on November 7, 2016
28 oct. 2016 05h33 HE
|
MorphoSys AG
MARTINSRIED / MUNICH, Germany, Oct. 28, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will publish its first nine months' 2016 results on November 7, 2016 at 7:00 am...
MorphoSys Receives Clinical Milestone for Start of Phase 1 Trial with Novel Cancer Antibody
20 oct. 2016 01h34 HE
|
MorphoSys AG
MARTINSRIED / MUNICH, Germany, Oct. 20, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that it has received a milestone payment from...
MorphoSys Presents Updated Clinical Results for MOR202 at Medical Conference
17 oct. 2016 01h35 HE
|
MorphoSys AG
MARTINSRIED / MUNICH, Germany, Oct. 17, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) presented updated safety and efficacy data from an ongoing phase...
MorphoSys Announces That Its Licensee Janssen Reports Positive Results From A Phase 3 Study of Guselkumab in Plaque Psoriasis
01 oct. 2016 06h51 HE
|
MorphoSys AG
Martinsried / Munich, Germany, Oct. 1, 2016 (GLOBE NEWSWIRE) -- Guselkumab Met Co-Primary Endpoints in Patients with Moderate to Severe Plaque Psoriasis
Janssen today presented results from a...
Ad hoc: MorphoSys Announces That Its Licensee Janssen Reports Positive Results From A Phase 3 Study of Guselkumab in Plaque Psoriasis
01 oct. 2016 06h48 HE
|
MorphoSys AG
Martinsried / Munich, Germany, Oct. 1, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that its licensee Janssen Research &...
MorphoSys and Galapagos Start First-In-Patient Dosing of IL-17C Antibody MOR106 in Atopic Dermatitis
29 sept. 2016 01h36 HE
|
MorphoSys AG
Ongoing phase 1 study in healthy volunteers now advanced to investigate MOR106 in patients with atopic dermatitis
Favorable safety results shown in healthy volunteers receiving single...
Lanthio Pharma Expands Management Team
19 sept. 2016 01h40 HE
|
MorphoSys AG
MARTINSRIED / MUNICH, Germany, Sept. 19, 2016 (GLOBE NEWSWIRE) -- The Dutch biopharmaceutical company Lanthio Pharma B.V., a wholly owned subsidiary of MorphoSys AG (FSE: MOR; Prime Standard Segment,...
MorphoSys Appoints Four R&D Experts to its Newly Formed Scientific Advisory Board
12 sept. 2016 01h38 HE
|
MorphoSys AG
MARTINSRIED / MUNICH, Germany, Sept. 12, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) today announced the appointment of four leading experts to its...